chartexchange

IPHA
Innate Pharma S.A. ADS
stockNASDAQADR

At CloseNov 18, 2026 3:59:30 PM EST
1.02USD-23.308%(-0.31)503,030
Pre-marketNov 18, 2026 9:27:30 AM EST
1.10USD-17.293%(-0.23)
After-hoursNov 18, 2026 4:00:30 PM EST
1.03USD+0.980%(+0.01)
Loading…
Loading…
113.93M
Healthcare
Biotechnology
HQ
Marseille, Paca, France
Previous Close
$1.33
Beta
1.53
52-Week High
$2.71 2026-08-13
52-Week Low
$1.00 2026-11-18
SMA 50
$1.57
SMA 200
$1.69
Avg. Vol 10D
73,917
Avg. Vol 30D
37,593
Avg. Vol 90D
123,799
Relative Vol
13.38
111.70M
68.87M
4.2000%
1,376
IPHA Profile

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma

IPHA Performance
PeriodPriceDateChangeBeta
1W1.492026-11-12-31.54%-11.056
1M1.462026-10-19-30.14%1.390
3M2.122026-08-19-51.89%1.386
6M2.032026-05-19-49.75%0.990
1Y1.792025-11-19-43.02%1.526
2Y1.492024-11-19-31.54%—
5Y5.012021-11-19-79.64%0.176
IPHA Stock Summary

Innate Pharma S.A. ADS (NASDAQ:IPHA) stock price today is $1.02, and today's volume is 503,030. IPHA is down 23.308% today. The 30 day average volume is 37,593. IPHA market cap is $113.93M with 111.70M shares outstanding.